Alzheimer’s & Dementia

Filter Your Results




Phase 3 Open Label Extension Study for BAN 2401 for Mild Cognitive Impairment Launches

Friday, March 08, 2019—A phase 3 study to investigate a humanized monoclonal antibody as a potential therapy for mild cognitive impairment from Alzheimer’s disease (AD)began this month. T…

Large Study Reveals New Risk Genes for Alzheimer’s Disease

Friday, March 01, 2019—Analysis of genetic data from more than 94,000 people has revealed new risk genes for Alzheimer’s disease (AD) and confirmed 20 known others. Researchers also reported t…

Therapeutic Benefits of Exercise Being Studied in Patients With Alzheimer’s

Wednesday, February 13, 2019—HealthPartners Neuroscience Center (St. Paul, MN) has announced they will be conducting the first study of the Muscle2Mind exercise program for patients with Alzheimer’s…

Warnings and Advisories Issued to 17 Companies for Products Illegally Marketed as Treatment for Alzheimer’s Disease

Tuesday, February 12, 2019—The Food and Drug Administration (FDA) posted 12 warning letters and 5 online advisory letters issued to 17 foreign and domestic companies that illegally sell more than 58 pro…

Study Shows That Learning Processes May Determine Severity of PTSD Symptoms

Friday, February 08, 2019—Findings from a study published in Nature Neurosciencereveal distinct patterns for how the brain and body respond when learning about danger and safety. The findings coul…

Level of Education Shown Not to Correlate to Rate of Cognitive Decline in Those With or Without Dementia

Thursday, February 07, 2019—Some studies have suggested that a higher level of education may correlate with lower incidence of dementia, which has been interpreted as suggesting education could increase …

Tau Pathology of Alzheimer’s Linked to Sleep-Wake Cycle

Wednesday, February 06, 2019—Poor sleep is a symptom of Alzheimer’s disease (AD) that worsens as the disease progresses and is also suggested to be an early symptom of AD. It has been known for some…

Genentech Discontinuing Phase 3 Clinical Studies of Crenezumab for Early Alzheimer’s Disease

Thursday, January 31, 2019—The phase 3 studies, CREAD 1 (NCT02670083) and CREAD 2 (NCT03114657), of crenezumab (Genetech, South San Francisco, CA), an investigational monoclonal antibody to am…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.